Cancers Treated:
Specializing In:
- Chronic myeloid leukemia (CML)
- Acute myeloid leukemia (AML)
- Myelodysplastic syndrome (MDS)
- Acute lymphoblastic leukemia (ALL)
- Myeloproliferative diseases (MPD)
- Hematologic Oncology
Research Interests:
- Management of CML with a focus on treatment free remission (TFR) and novel treatments
- Clinical informatics and optimization of the Electronic Health Record (EHR) to enhance patient care
Positions
Roswell Park Comprehensive Cancer Center
- Associate Professor
- Associate Chief Medical Information Officer - Medicine
- Department of Medicine
Background
Education and Training
- MD - Columbia University College of Physicians & Surgeons, New York, NY
- MS - Medical Informatics, Northwestern University, Evanston, IL
Residency
- University of Pennsylvania, Philadelphia, PA
Fellowship
- University of Pennsylvania, Philadelphia, PA
Board Certification
- Hematology, American Board of Internal Medicine
- Clinical Informatics, American Board of Preventative Medicine
Clinical Trials
Featured on CancerTalk
Publications
Winn AN, Atallah E, Cortes J, Deininger MWN, Kota V, Larson RA, Moore JO, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Shah NP, Thompson JE, Flynn KE. Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. JAMA Netw Open. 2023 Dec 1;6(12):e2347950. doi: 10.1001/jamanetworkopen.2023.47950. PubMed PMID: 38109114; PubMed Central PMCID: PMC10728762.
Flynn KE, Atallah E, Lin L, Shah NP, Silver RT, Larson RA, Panilla-Ibarz J, Thompson JE, Oehler VG, Radich JP, Kota V, Mauro MJ, Schiffer CA, Cortes J, Weinfurt KP. Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. Haematologica. 2022 Nov 1;107(11):2641-2649. doi: 10.3324/haematol.2021.280377. PubMed PMID: 35511672; PubMed Central PMCID: PMC9614525.
Kasner MT, Halloran MB, Pan J, Ritchie EK, Fetterly GJ, Kramer D, Hangauer DG, Thompson JE. A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia. Invest New Drugs. 2022 Aug;40(4):773-781. doi: 10.1007/s10637-022-01255-1. Epub 2022 May 17. PubMed PMID: 35579731.
Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. J Natl Cancer Inst. 2022 Jan 11;114(1):160-164. doi: 10.1093/jnci/djab184. PubMed PMID: 34491344; PubMed Central PMCID: PMC8755495.
Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan 1;7(1):42-50. doi: 10.1001/jamaoncol.2020.5774. PubMed PMID: 33180106; PubMed Central PMCID: PMC7662490.